Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Image-Guided Irreversible Electroporation for the Treatment of Localized Prostate Cancer].

Aktuelle Urologie·2026
Same author

CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy.

Histology and histopathology·2025
Same author

ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by regulating glycolysis.

Oncogene·2025
Same author

Long-Term Oncologic Outcomes of Image-Guided Irreversible Electroporation for Localized Prostate Cancer.

Cardiovascular and interventional radiology·2024
Same author

Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.

International journal of molecular sciences·2024
Same author

Clinical implications of AGR2 in primary prostate cancer: Results from a large-scale study.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2024

Related Experiment Video

Updated: May 29, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Is there an optimal prostate-specific antigen threshold for prostate biopsy?

Carsten Stephan1, Kurt Miller, Klaus Jung

  • 1Department of Urology, Charité University Medicine Berlin, Charitéplatz 1, Berlin D 10117, Germany. carsten.stephan@charite.de

Expert Review of Anticancer Therapy
|September 16, 2011
PubMed
Summary

Prostate-specific antigen (PSA) is crucial for early prostate cancer (PCa) detection. Lowering PSA cut-offs improves sensitivity but may detect insignificant cancers, necessitating careful interpretation alongside other factors for biopsy decisions.

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: May 29, 2026

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Area of Science:

  • Urology
  • Oncology
  • Biomarker Research

Background:

  • Prostate-specific antigen (PSA) is the primary biomarker for early prostate cancer (PCa) detection.
  • Elevated PSA levels correlate with an increased risk of PCa.
  • The traditional PSA cutoff of 4 µg/l was revised due to similar PCa detection rates in the 2-4 µg/l and 4-10 µg/l ranges.

Purpose of the Study:

  • To evaluate the effectiveness of various PSA cutoffs in balancing PCa detection sensitivity and specificity.
  • To discuss strategies for enhancing PSA test specificity in prostate cancer screening.
  • To emphasize the importance of integrating PSA with other clinical factors for biopsy decisions.

Main Methods:

  • Analysis of PSA values and associated prostate cancer detection rates.
  • Review of the impact of lowering PSA cutoffs on sensitivity and the detection of insignificant cancers.
  • Exploration of methods to improve PSA test specificity, including PSA derivatives and multivariate models.

Main Results:

  • Lowering PSA cutoffs increases sensitivity but also leads to a higher detection rate of clinically insignificant prostate cancers.
  • Current PSA cutoffs (2.5, 3, or 4 µg/l) represent a compromise between detecting relevant PCa and avoiding overdiagnosis.
  • Enhanced specificity can be achieved through PSA derivatives, isoforms, novel biomarkers, and multivariate analyses.

Conclusions:

  • PSA remains a valuable tool for early prostate cancer detection, but its interpretation requires careful consideration.
  • Optimizing PSA cutoff values and employing advanced methods are essential to improve the accuracy of prostate cancer diagnosis.
  • A comprehensive approach, integrating PSA results with clinical factors, is recommended for making informed prostate biopsy decisions.